Cargando…
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
INTRODUCTION AND HYPOTHESIS: The objective of this study was to assess the tolerability and treatment preference in patients with overactive bladder (OAB) treated with mirabegron or tolterodine. METHODS: This was a two-period, 8-week crossover, double-blind, phase IV study (PREFER; NCT02138747) in t...
Autores principales: | Staskin, David, Herschorn, Sender, Fialkov, Jonathan, Tu, Le Mai, Walsh, Terry, Schermer, Carol R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780540/ https://www.ncbi.nlm.nih.gov/pubmed/28620791 http://dx.doi.org/10.1007/s00192-017-3377-5 |
Ejemplares similares
-
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018) -
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020) -
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
por: Griebling, Tomas L., et al.
Publicado: (2020) -
Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014) -
Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)